Therapeutic interventions in systemic sclerosis.
van den Hoogen
F H
FH
Department of Rheumatology, University Hospital Nijmegen, The Netherlands.
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D009426:Netherlands; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D008727:Methotrexate